Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Pharmaron Stages $434 Million Hong Kong IPO, after Completing Shenzhen IPO in January

publication date: Nov 29, 2019

Pharmaron Beijing staged a $434 million Hong Kong IPO to expand its international CRO operations. In January, Pharmaron completed a $76 million IPO on the Shenzhen Exchange, and its stock price has quadrupled since its debut. The company said the dual registration will support its growth plans, including developing its global integrated service platform, R&D capability, M&A and strategic investments. Founded in 2004, with facilities in China, the US and UK staffed by over 7,000 employees, Pharmaron offers R&D services to partners in North America, Europe, Japan and China. More details....

Stock Symbols: (SHZ: 300759; HK: 3759)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China